Aggrenox To Treat Acute Covid-19

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions
Covid19
Interventions
DRUG

Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care

Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.

OTHER

Standard of care

Participants will receive standard care starting on the day of enrollment for a total of 2 weeks. Standard of care treatment consist of an intravenous Remidesivir 200 mg loading dose and then 100 mg/daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg/daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients are discharged before 10 days, they are prescribed oral decadron 6 mg daily to complete the course of 10 days.

Trial Locations (1)

07103

Rutgers New Jersey Medical School University Hospital, Newark

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER

NCT04410328 - Aggrenox To Treat Acute Covid-19 | Biotech Hunter | Biotech Hunter